Why PNH Is a Complement Disease — and Why C5 Inhibition Isn’t Enough

Paroxysmal nocturnal hemoglobinuria is a clonal hematopoietic stem cell disorder caused by somatic mutations in the PIGA gene, resulting in loss of GPI-anchored complement regulatory proteins — specifically CD55 and CD59 — on the surface of red blood cells, platelets, and white blood cells. Without these surface regulators, affected cells are rendered permanently vulnerable to complement-mediated attack. The disease is life-threatening, rare, and, until the arrival of complement inhibitors, had no disease-modifying therapy.

The molecular pathology of PNH generates two mechanistically distinct forms of hemolysis. Intravascular hemolysis (IVH) is driven by terminal complement pathway activation at the membrane attack complex (C5b-9), which directly lyses red blood cells within circulation. Extravascular hemolysis (EVH) is mediated by C3b and C3d opsonization of GPI-deficient erythrocytes and their subsequent clearance by the reticuloendothelial system. This distinction is not academic — it is the central clinical problem that defines the competitive landscape of PNH therapy in 2025.

Eculizumab — and its long-acting successor ravulizumab — block C5 cleavage, preventing MAC (C5b-9) formation and effectively controlling IVH. Ravulizumab’s engineered half-life of approximately 50 days (versus eculizumab’s approximately 12 days) enables an extended 8-week intravenous infusion interval, improving on the every-2-week burden of eculizumab. According to data published in PubMed-indexed Phase 3 trials, ravulizumab demonstrated non-inferiority to eculizumab on LDH normalization and patient-reported outcomes, cementing its position as the dominant standard of care prior to iptacopan’s commercial entry.

The critical limitation, however, is structural: C5 inhibition leaves the upstream alternative pathway amplification loop fully intact. C3b continues to deposit on the surface of GPI-deficient PNH red blood cells, opsonizing them for splenic and hepatic clearance. A proportion of patients treated with anti-C5 agents therefore experience persistent anemia — they have controlled IVH but uncontrolled EVH — and fail to achieve hemoglobin normalization despite effective LDH suppression. This gap is the scientific and commercial opening that iptacopan was designed to exploit.

How Iptacopan’s Factor B Mechanism Addresses the EVH Gap

Iptacopan (LNP023) closes the EVH gap by intervening in the complement cascade at a point upstream of both C3 and C5. Factor B is a serine protease of the alternative pathway that associates with C3b to form the C3bBb convertase — the amplification enzyme responsible for generating the C3b fragments that opsonize PNH red blood cells. By binding directly to Factor B and preventing its incorporation into this convertase, iptacopan halts the amplification loop before C3 cleavage occurs, simultaneously preventing both IVH and EVH.

This proximal mechanism of action is the pharmacological basis for iptacopan’s differentiation from C5-targeting biologics. Patent records filed by Novartis describe small-molecule binding to the active site or allosteric pockets of Factor B, with selectivity profiles distinguishing iptacopan from Factor D and other serine proteases. The oral, twice-daily administration route is an additional structural differentiator: iptacopan patients do not require infusion center visits, removing a significant logistical burden that is intrinsic to ravulizumab’s delivery model.

The breadth of pathway blockade afforded by Factor B inhibition — covering both arms of hemolysis — is the central mechanistic argument for iptacopan’s clinical superiority claim. Retrieved literature by Schubart et al. (2022) describes the pharmacology of LNP023 and its selectivity profile, while Risitano et al. (2023) provide the clinical translation evidence from PNH patient data. The convergence of mechanistic rationale and Phase 3 clinical evidence positions iptacopan not merely as an alternative to anti-C5 therapy but as a potential standard-of-care replacement for patients with residual anemia — and as a monotherapy option for complement-inhibitor-naïve patients.

“Factor B inhibition upstream of C3 is mechanistically positioned to simultaneously prevent both intravascular and extravascular hemolysis — addressing a recognized limitation of C5 inhibitors that leave the proximal amplification loop intact.”

The Proximal Complement Inhibitor Battleground: Iptacopan, Danicopan, and Pegcetacoplan

The proximal complement inhibitor class — agents targeting Factor B, Factor D, or C3 itself — has become the dominant R&D battleground for PNH commercial differentiation. Three distinct agents from three different companies now compete in or adjacent to this space, each with a different molecular target, route of administration, and strategic positioning relative to ravulizumab.

Danicopan (ALXN2040): Oral Factor D Inhibitor as Combination Add-On

Danicopan, developed by Alexion/AstraZeneca, targets Factor D — the obligate activating protease for the alternative pathway C3 convertase. Factor D catalyzes the cleavage of Factor B within the forming convertase; its inhibition therefore also prevents C3bBb assembly, albeit via a different enzymatic target than iptacopan. Crucially, danicopan has been pursued primarily as an add-on to ravulizumab rather than as a monotherapy replacement. The strategic logic is to retain IVH control with the established C5 inhibitor while using oral Factor D inhibition to address breakthrough EVH — a combination approach that preserves Alexion/AstraZeneca’s existing ravulizumab revenue base while extending its reach into the EVH population. The ALPHA trial evaluated this combination strategy in Phase 3, with endpoints focused on hemoglobin improvement on top of ravulizumab background therapy.

Pegcetacoplan: Subcutaneous C3 Inhibitor

Pegcetacoplan, developed by Apellis Pharmaceuticals, is a PEGylated C3-targeting peptide administered subcutaneously. By blocking C3 directly — the convergence node of both classical and alternative pathways — pegcetacoplan intercepts complement activation before any downstream effector mechanism can form, preventing both MAC formation and C3b opsonization. The PEGASUS Phase 3 trial demonstrated hemoglobin improvement with subcutaneous C3 inhibition versus eculizumab, establishing proof-of-concept for the clinical value of proximal complement inhibition ahead of iptacopan’s approval. Pegcetacoplan’s subcutaneous route distinguishes it from both intravenous ravulizumab and oral iptacopan, occupying an intermediate position on the convenience spectrum.

The competitive distinction between these three proximal agents is not merely mechanistic — it is strategic. Iptacopan and pegcetacoplan are positioned as monotherapy replacements for anti-C5 agents in patients with residual anemia, while danicopan is positioned as a combination add-on that preserves the incumbent therapy. This reflects the divergent commercial interests of Novartis (seeking to capture the entire PNH patient), Apellis (seeking switch patients), and Alexion/AstraZeneca (seeking to retain existing ravulizumab patients while extending their value proposition). As documented by regulatory bodies including EMA and FDA, all three agents have received or sought regulatory review in PNH.

Pivotal Trial Signals and the Hemoglobin Normalization Benchmark

The clinical trial architecture for iptacopan in PNH represents a deliberate effort to establish hemoglobin normalization — rather than LDH normalization — as the defining efficacy benchmark for the field. This endpoint selection is strategically significant: it reframes what “treatment success” means in PNH and sets a bar that anti-C5 agents cannot routinely meet.

The APPLY-PNH Phase 3 trial enrolled PNH patients who had residual anemia on anti-C5 therapy (ravulizumab or eculizumab). The primary endpoint of hemoglobin normalization (Hb ≥12 g/dL) was reportedly achieved at rates significantly exceeding control — a clinically meaningful threshold representing the absence of transfusion-dependent anemia. This is the basis for iptacopan’s regulatory approval submissions in both the United States and Europe. The trial’s design — enrolling patients already established on C5 inhibition — directly addresses the largest near-term commercial opportunity: the pool of patients currently on ravulizumab who remain anemic.

The APPOINT-PNH trial evaluated iptacopan monotherapy in complement-inhibitor-naïve PNH patients, further broadening the potential commercial population beyond anti-C5 inadequate responders. This arm is strategically important because it positions iptacopan as a first-line option rather than purely a rescue or switch therapy, potentially capturing newly diagnosed patients before they initiate ravulizumab.

By contrast, the ravulizumab Phase 3 program (ALXN1210-PNH-301 and -302) used LDH normalization as its primary efficacy measure — a biochemical marker of intravascular hemolysis that does not capture the anemia burden driven by EVH. The endpoint divergence between the two programs is not coincidental: it reflects the mechanistic difference between C5 inhibition (which controls IVH and LDH) and Factor B inhibition (which controls both IVH and EVH, enabling hemoglobin normalization). As WIPO-tracked patent filings and published clinical data together suggest, the field is moving toward hemoglobin normalization as the new efficacy standard — a shift that inherently advantages proximal pathway inhibitors over terminal complement agents.

The PEGASUS trial for pegcetacoplan provided an earlier proof-of-concept for this endpoint strategy, demonstrating hemoglobin improvement with subcutaneous C3 inhibition versus eculizumab and establishing that proximal complement inhibition can achieve what C5 inhibition cannot. Iptacopan’s APPLY-PNH data built on this precedent with an oral agent and a head-to-head design against the current standard of care.

Patent Landscape and IP Strategy: Novartis, Alexion, and Apellis

The patent landscape for complement inhibition in PNH reflects a clear three-way IP segmentation between Novartis (Factor B), Alexion/AstraZeneca (C5 + Factor D), and Apellis (C3) — each company having staked out a distinct molecular territory within the complement cascade. This segmentation is not accidental; it mirrors the competitive dynamics of the clinical landscape and signals where each company’s long-term IP defense is anchored.

Novartis AG holds the dominant IP position in the Factor B inhibitor space within this dataset, with US patent records describing small-molecule Factor B inhibition as a therapeutic strategy for PNH and related complement-mediated conditions. Critically, Novartis patent filings extend well beyond PNH to cover IgA nephropathy, C3 glomerulopathy, and geographic atrophy — conditions where complement alternative pathway dysregulation is also pathologically relevant. This breadth suggests that PNH is serving as a regulatory and commercial proof-of-concept for a much larger Factor B inhibitor franchise, and that the IP estate being built around iptacopan is designed to defend a multi-indication platform rather than a single orphan drug.

Alexion Pharmaceuticals / AstraZeneca occupies a dual-track IP position: the dominant holder of anti-C5 antibody engineering patents (ravulizumab) and an active developer of proximal complement approaches via danicopan. Patent records in this dataset describe combination approaches covering danicopan with ravulizumab for the EVH population. This dual-track strategy is a textbook hedge: if proximal complement inhibition becomes the standard of care, Alexion/AstraZeneca has IP coverage in Factor D; if C5 inhibition retains dominance, ravulizumab remains protected. The Factor B inhibitor space, however, is currently dominated by Novartis IP, creating a clear gap in Alexion/AstraZeneca’s portfolio that danicopan does not fill.

Apellis Pharmaceuticals holds patent records for pegcetacoplan as a C3 inhibitor, positioning it as a third competitive force with a distinct molecular target and subcutaneous delivery mechanism. The C3 target is the broadest possible intervention point — blocking all downstream complement effector mechanisms regardless of initiation pathway — but also carries theoretical safety considerations around pan-complement suppression that are absent from more selective upstream inhibitors.

Emerging pipeline entries targeting alternative pathway nodes — Factor D, properdin (Factor P), and MASP-3 — as orally bioavailable small molecules signal that the field is directionally moving toward fully oral complement therapy across multiple indications. Retrieved literature identifies pharmacokinetic optimization and selectivity as key development challenges for next-generation agents, areas where the existing approved agents (iptacopan, danicopan) provide both a competitive benchmark and a freedom-to-operate reference point for patent strategy.

What Oral Complement Therapy Means for the Future of PNH Treatment

Oral administration represents a fundamental competitive differentiator for iptacopan over intravenous ravulizumab — one that extends beyond pharmacology into the practical reality of living with a chronic rare disease. Iptacopan’s twice-daily oral regimen is mechanistically decoupled from the infusion center infrastructure that underpins ravulizumab’s commercial model: no scheduled hospital or clinic visits, no intravenous access requirements, no 8-week appointment cadence. In chronic rare disease therapy, dosing convenience and route of administration are consistently associated with switching behavior, and iptacopan’s oral formulation removes a structural barrier to patient preference that ravulizumab cannot address without a fundamentally different delivery technology.

“Hemoglobin normalization (Hb ≥12 g/dL) as iptacopan’s primary Phase 3 endpoint sets a clinically higher bar than LDH normalization — the traditional anti-C5 efficacy measure — potentially redefining treatment response standards across the entire PNH field.”

The hemoglobin normalization endpoint adopted in APPLY-PNH has implications beyond iptacopan’s own label. By demonstrating that a PNH therapy can achieve Hb ≥12 g/dL normalization in a significant proportion of patients — a threshold representing functional absence of anemia — iptacopan’s trial program implicitly reframes what physicians, payers, and patients should expect from PNH treatment. If hemoglobin normalization becomes the accepted benchmark for treatment adequacy, anti-C5 agents face a structural efficacy disadvantage that cannot be resolved by extended dosing intervals or antibody engineering alone.

Alexion/AstraZeneca’s dual-track IP position signals awareness of this risk: the danicopan add-on strategy is designed to rescue ravulizumab’s hemoglobin profile without abandoning the C5 inhibitor franchise. Whether combination therapy (ravulizumab + danicopan) can match iptacopan monotherapy on hemoglobin normalization — and whether payers will reimburse a two-drug combination at the cost premium that implies — are the pivotal commercial questions that will determine ravulizumab’s long-term position in PNH.

Beyond PNH, the strategic implications of iptacopan’s commercial launch extend across the complement inhibitor field. The approval of an oral Factor B inhibitor in a rare, well-characterized complement-mediated disease provides a regulatory template and a clinical proof-of-concept for Factor B inhibition in IgA nephropathy, C3 glomerulopathy, and geographic atrophy — all larger patient populations than PNH. As documented by patent databases including those maintained by the EPO, Novartis’s filing strategy anticipates exactly this expansion, making the PNH commercial launch strategically important as a foundation for a multi-indication complement platform rather than as an endpoint in itself.